Association between nonalcoholic fatty liver disease and cardiac function and structure—a meta-analysis

Borges‐Canha, Marta; Neves, João Sérgio; Libânio, Diogo; Hafe, Madalena von; Vale, Catarina; Araújo-Martins, Miguel; Leite, Ana Rita; Pimentel‐Nunes, Pedro; Carvalho, Davide; Leite‐Moreira, Adelino F.

doi:10.1007/s12020-019-02070-0

Cited by 30 publications

(29 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the above‐mentioned meta‐analyses on the association between NAFLD and structural or functional parameters may imply a higher probability of cardiomyopathy and heart failure in NAFLD patients, 33,34 these are referred mainly to subclinical alterations. Limited data from observational studies suggest an association between NAFLD and clinically overt heart failure.…”

Section: Clinical Evidence On the Association Between Nafld And Cvdmentioning

confidence: 99%

Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations

Polyzos

Kechagias

Tsochatzis

2021

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background There are increasing data on the association between non‐alcoholic fatty liver disease (NAFLD) and cardiovascular diseases (CVD). Aim To summarise evidence on the association between NAFLD and CVD in the clinical setting and provide potential therapeutic implications. Methods We searched PubMed. Evidence was primarily derived from meta‐analyses. and then, if data were insufficient, from clinical trials, and then from observational studies. Results NAFLD has been linked to arterial hypertension, arterial stiffness, atherosclerosis, coronary artery disease, atrial fibrillation and aortic valvular sclerosis. Advanced liver fibrosis is a crucial prognostic factor for end‐stage liver disease and for cardiovascular and overall mortality. Weight loss through lifestyle modifications (diet and exercise) remains the cornerstone of the management of both NAFLD and CVD, but is difficult to achieve and possibly more difficult to sustain long term. Therefore, pharmacological management of NAFLD seems to be important, although no licenced medication currently exists. Pioglitazone, proposed for non‐alcoholic steatohepatitis (NASH) by most guidelines, increases weight and should be avoided in congestive heart failure. Statins should not be avoided in NAFLD patients at risk for CVD. Glucagon‐like peptide 1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors, two classes of anti‐diabetic drugs, have shown promising results in NAFLD and CVD, but more studies with hard end points are needed. Obeticholic acid, a promising medication for NASH under investigation, should be carefully considered, owing to its adverse effect on lipid profile. Conclusions NAFLD is associated with CVD, which may have certain clinical and therapeutic implications.

show abstract

Section: Clinical Evidence On the Association Between Nafld And Cvdmentioning

confidence: 99%

Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations

Polyzos

Kechagias

Tsochatzis

2021

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…A meta-analysis carried out by Borges et al noted an important relationship between NAFLD and higher left atrium diameter and ratio between left atrial volume and body surface area [118]. The left atrium is responsible for the filling of the left ventricle, and, on the other hand, the left ventricle function influences the left atrium's function throughout the cardiac cycle [119].…”

Section: Increased Left Ventricular Mass and Interventricular Septum Thicknessmentioning

confidence: 99%

Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management

et al. 2021

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) has a growing prevalence in recent years. Its association with cardiovascular disease has been intensively studied, and certain correlations have been identified. The connection between these two entities has lately aroused interest regarding therapeutic management. In order to find the best therapeutic options, a detailed understanding of the pathophysiology that links (NAFLD) to cardiovascular comorbidities is needed. This review focuses on the pathogenic mechanisms that are behind these two diseases and on the therapeutic management available at this time.

show abstract

“…In 30-40% of patients, hepatic steatosis evolves to steatohepatitis, which is characterized by steatosis with hepatocyte injury (ballooning), inflammation, and increased risk for liver fibrosis, cirrhosis and/or carcinogenesis [5,6]. Steatohepatitis is also associated with increased risk of cardiovascular adverse events, which represent the main MAFLD-related cause of death [8]. MAFLD is recognized as the hepatic manifestation of metabolic syndrome, and over-nutrition with visceral adiposity, diabetes, insulin resistance and dyslipidaemia are well-known related risk factors [5,9,10].…”

Section: Introductionmentioning

confidence: 99%

Administration of Protein Hydrolysates from Anchovy (Engraulis Encrasicolus) Waste for Twelve Weeks Decreases Metabolic Dysfunction-Associated Fatty Liver Disease Severity in ApoE–/–Mice

Abbate

Macrı̀

Capparucci

et al. 2020

Animals

View full text Add to dashboard Cite

Metabolic dysfunction-associated fatty liver disease (MAFLD) includes several diseases, ranging from simple steatosis to steatohepatitis, fibrosis and cirrhosis. Fish-rich diets are considered helpful in the prevention of MAFLD, and the enzymatic hydrolysis of fish waste has been explored as a means of obtaining high-value protein hydrolysates, which have been proven to exert beneficial bioactivities including anti-obesity and hypocholesterol effects. This study aimed to assess the effect of the administration of protein hydrolysates from anchovy waste (APH) for 12 weeks on attenuated high-fat diet-induced MAFLD in apolipoprotein E-knockout mice (ApoE–/–). Thirty ApoE–/– mice were divided into two groups (n = 15/group) and fed a high-fat diet (HFD), with and without the addition of 10% (w/w) APH. After 12 weeks, serum and hepatic lipid profiles, hepatic enzyme activities, liver histology and immunohistochemistry were analyzed to assess hepatic steatosis, inflammation and fibrosis. Twelve-weeks on a 10% (w/w) APH diet reduces total cholesterol and triglyceride serum levels, hepatic enzyme activity and hepatic triacylglycerol content (p < 0.0001), and results in a reduction in hepatic fat accumulation and macrophage recruitment (p < 0.0001). The results suggest that a 10% APH diet has an anti-obesity effect, with an improvement in lipid metabolism, hepatic steatosis and liver injury as a result of a high-fat diet. Protein hydrolysates from fish waste may represent an efficient nutritional strategy in several diseases, and their use as nutraceuticals is worthy of future investigation.

show abstract

Association between nonalcoholic fatty liver disease and cardiac function and structure—a meta-analysis

Cited by 30 publications

References 27 publications

Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations

Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations

Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management

Administration of Protein Hydrolysates from Anchovy (Engraulis Encrasicolus) Waste for Twelve Weeks Decreases Metabolic Dysfunction-Associated Fatty Liver Disease Severity in ApoE–/–Mice

Contact Info

Product

Resources

About